• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗肾上腺皮质功能不全的双相释放氢化可的松：一项系统评价

Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.

作者信息

Mongioì Laura Maria, Condorelli Rosita Angela, Barbagallo Federica, La Vignera Sandro, Calogero Aldo Eugenio

机构信息

Department of Clinical and Experimental Medicine, University of Catania, Via S. Sofia 78, 95123, Catania, Italy.

出版信息

Endocrine. 2020 Mar;67(3):507-515. doi: 10.1007/s12020-020-02187-7. Epub 2020 Jan 11.

DOI:10.1007/s12020-020-02187-7
PMID:31927751
Abstract

Dual-release hydrocortisone is a new hydrocortisone formulation developed to improve the pharmacokinetic and the pharmacodynamic profiles and patient compliance. The aim of this review is to summarize the main knowledge on dual-release hydrocortisone, with particular attention to pharmacokinetics, metabolic and health-related quality-of-life aspects, bone health and drug safety.

摘要

双相释放氢化可的松是一种新开发的氢化可的松制剂，旨在改善药代动力学和药效学特征以及患者的依从性。本综述的目的是总结关于双相释放氢化可的松的主要知识，特别关注药代动力学、代谢及与健康相关的生活质量方面、骨骼健康和药物安全性。

相似文献

1
Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.用于治疗肾上腺皮质功能不全的双相释放氢化可的松：一项系统评价
Endocrine. 2020 Mar;67(3):507-515. doi: 10.1007/s12020-020-02187-7. Epub 2020 Jan 11.
2
Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.每日一次、改良型释放氢可体松与标准糖皮质激素疗法对肾上腺功能不全患者代谢和固有免疫的影响（DREAM）：一项单盲、随机对照试验。
Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185. doi: 10.1016/S2213-8587(17)30398-4. Epub 2017 Dec 8.
3
Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments.改善肾上腺皮质功能不全患者的治疗效果：当前及未来治疗方法综述
Curr Med Res Opin. 2014 Sep;30(9):1833-47. doi: 10.1185/03007995.2014.925865. Epub 2014 Jun 9.
4
Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.从速释到分段双释放氢化可的松的转换可能改善选定的原发性肾上腺功能不全患者的代谢控制和生活质量。
Front Endocrinol (Lausanne). 2021 Feb 1;11:610904. doi: 10.3389/fendo.2020.610904. eCollection 2020.
5
Exploring sexual function in adrenal insufficiency: findings from the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent therapy in hypocortisolism (DREAM) trial.探索肾上腺皮质功能减退症患者的性功能：双相释放氢化可的松与传统糖皮质激素替代疗法治疗肾上腺皮质功能减退症（DREAM）试验的结果
Andrology. 2025 Feb;13(2):302-313. doi: 10.1111/andr.13635. Epub 2024 Mar 28.
6
Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment.继发性肾上腺皮质功能减退：从病理生理学到缓释氢化可的松治疗的潜在作用
Minerva Endocrinol. 2018 Jun;43(2):183-197. doi: 10.23736/S0391-1977.17.02701-8. Epub 2017 Jul 27.
7
Therapies for adrenal insufficiency.肾上腺功能不全的治疗方法。
Expert Opin Pharmacother. 2007 Jun;8(9):1283-91. doi: 10.1517/14656566.8.9.1283.
8
Use of dual-release hydrocortisone in adrenal insufficiency.
Eur J Endocrinol. 2021 Aug 4;185(3):L9-L10. doi: 10.1530/EJE-21-0418.
9
Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery.预防肾上腺危象：大应激与应激剂量氢化可的松给药后皮质醇反应的比较。
J Clin Endocrinol Metab. 2020 Jul 1;105(7):2262-74. doi: 10.1210/clinem/dgaa133.
10
Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme).氢化可的松速释颗粒制剂Alkindi®，用于治疗小儿肾上腺皮质功能不全（Infacort研发项目）。
Expert Rev Endocrinol Metab. 2018 May;13(3):119-124. doi: 10.1080/17446651.2018.1455496. Epub 2018 Mar 26.

引用本文的文献

1
Endothelial dysfunction in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: current knowledge and novel biomarkers.21-羟化酶缺乏所致先天性肾上腺皮质增生症中的内皮功能障碍：当前认知与新型生物标志物
Front Endocrinol (Lausanne). 2025 Jun 3;16:1581681. doi: 10.3389/fendo.2025.1581681. eCollection 2025.
2
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia.先天性肾上腺皮质增生症的心脏代谢方面
Endocr Rev. 2025 Jan 10;46(1):80-148. doi: 10.1210/endrev/bnae026.
3
Unveiling the dynamic and thermodynamic interactions of hydrocortisone with β-cyclodextrin and its methylated derivatives through insights from molecular dynamics simulations.

本文引用的文献

1
Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study.双释放氢化可的松改善继发性肾上腺功能不全患者的肝脂肪变性：一项真实世界研究。
Ther Adv Endocrinol Metab. 2019 Aug 28;10:2042018819871169. doi: 10.1177/2042018819871169. eCollection 2019.
2
Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency.肾上腺功能不全中双相释放氢化可的松与传统糖皮质激素的比较
Endocr Connect. 2019 Jul 1;8(7):853-862. doi: 10.1530/EC-19-0176.
3
Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.
通过分子动力学模拟的见解揭示氢化可的松与β-环糊精及其甲基化衍生物的动力学和热力学相互作用。
Sci Rep. 2024 May 31;14(1):12495. doi: 10.1038/s41598-024-63034-7.
4
Lewis acid-driven self-assembly of diiridium macrocyclic catalysts imparts substrate selectivity and glutathione tolerance.路易斯酸驱动的二铱大环催化剂自组装赋予底物选择性和谷胱甘肽耐受性。
Chem Sci. 2023 Sep 4;14(37):10264-10272. doi: 10.1039/d3sc02836d. eCollection 2023 Sep 27.
5
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.双重释放氢化可的松在自身免疫性原发性肾上腺皮质功能不全患者中的骨骼安全性
Front Endocrinol (Lausanne). 2023 Sep 11;14:1234237. doi: 10.3389/fendo.2023.1234237. eCollection 2023.
6
Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.评估治疗依从性对于确定盐皮质激素治疗的充分性至关重要。
Endocr Connect. 2023 Aug 2;12(9):e230059. doi: 10.1530/EC-23-0059.
7
Glucocorticoid replacement therapy for primary and secondary adrenal insufficiency and their impact on cognition.糖皮质激素替代疗法治疗原发性和继发性肾上腺功能不全及其对认知的影响。
Front Endocrinol (Lausanne). 2023 Mar 17;14:1153595. doi: 10.3389/fendo.2023.1153595. eCollection 2023.
8
Salivary cortisol levels during Ramadan fasting in hydrocortisone-treated secondary adrenal insufficiency patients.氢化可的松治疗的继发性肾上腺皮质功能不全患者在斋月禁食期间的唾液皮质醇水平。
Endocrine. 2020 Nov;70(2):404-411. doi: 10.1007/s12020-020-02452-9. Epub 2020 Aug 12.
艾迪生病中的双相释放氢化可的松——文献综述
Eur Endocrinol. 2014 Feb;10(1):75-78. doi: 10.17925/EE.2014.10.01.75. Epub 2014 Feb 28.
4
Multiple benefits from dual release hydrocortisone: a "hard" view from bones.双重释放氢化可的松的多重益处：来自骨骼的“硬”视角
Endocrine. 2018 Aug;61(2):177-179. doi: 10.1007/s12020-018-1628-y. Epub 2018 May 17.
5
Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis.双释放氢化可的松治疗肾上腺功能减退的糖尿病前期患者胰岛素敏感性和分泌改善：36 个月回顾性分析。
Clin Endocrinol (Oxf). 2018 May;88(5):665-672. doi: 10.1111/cen.13554. Epub 2018 Feb 19.
6
PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study.PlenadrEMA：双释放型与传统氢化可的松对疲劳的影响，通过生态瞬时评估法测量：一项开放标签转换试点研究的研究方案
BMJ Open. 2018 Jan 23;8(1):e019487. doi: 10.1136/bmjopen-2017-019487.
7
Bone safety of dual-release hydrocortisone in patients with hypopituitarism.垂体功能减退患者中双相释放氢化可的松的骨骼安全性
Endocrine. 2018 Jun;60(3):528-531. doi: 10.1007/s12020-017-1512-1. Epub 2018 Jan 8.
8
Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life.双释放氢化可的松治疗：糖代谢情况及与健康相关的生活质量
Endocr Connect. 2018 Jan;7(1):211-219. doi: 10.1530/EC-17-0368. Epub 2017 Dec 12.
9
Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.每日一次、改良型释放氢可体松与标准糖皮质激素疗法对肾上腺功能不全患者代谢和固有免疫的影响（DREAM）：一项单盲、随机对照试验。
Lancet Diabetes Endocrinol. 2018 Mar;6(3):173-185. doi: 10.1016/S2213-8587(17)30398-4. Epub 2017 Dec 8.
10
Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.应用双能 X 射线吸收法评估 Addison 病患者糖皮质激素和盐皮质激素替代治疗后的椎体骨折情况。
Endocrine. 2018 Feb;59(2):319-329. doi: 10.1007/s12020-017-1380-8. Epub 2017 Aug 9.